应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
00867 康哲药业
已收盘 12-20 16:08:10
7.410
+0.010
+0.14%
最高
7.470
最低
7.250
成交量
638.05万
今开
7.250
昨收
7.400
日振幅
2.97%
总市值
180.77亿
流通市值
180.77亿
总股本
24.40亿
成交额
4,718万
换手率
0.26%
流通股本
24.40亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
康哲药业12月16日遭主力抛售922万元 环比增加479.87%
市场透视 · 12-16
康哲药业12月16日遭主力抛售922万元 环比增加479.87%
南向资金12月13日净卖出康哲药业203.50万股 连续3日减持
市场透视 · 12-16
南向资金12月13日净卖出康哲药业203.50万股 连续3日减持
康哲药业12月11日遭主力抛售554万元 环比增加282.07%
市场透视 · 12-11
康哲药业12月11日遭主力抛售554万元 环比增加282.07%
康哲药业(00867)创新药莱芙兰®开出全国首批处方 助力结直肠病变精准诊断
智通财经 · 12-10
康哲药业(00867)创新药莱芙兰®开出全国首批处方 助力结直肠病变精准诊断
康哲药业12月09日遭主力抛售221万元 环比增加718.52%
市场透视 · 12-09
康哲药业12月09日遭主力抛售221万元 环比增加718.52%
康哲药业12月05日主力资金流出52万元 连续3日减仓
市场透视 · 12-05
康哲药业12月05日主力资金流出52万元 连续3日减仓
高盛:维持康哲药业“买入”评级 目标价上调至12.82港元
新浪港股 · 12-05
高盛:维持康哲药业“买入”评级 目标价上调至12.82港元
高盛:维持康哲药业(00867)“买入”评级 目标价上调至12.82港元
智通财经 · 12-05
高盛:维持康哲药业(00867)“买入”评级 目标价上调至12.82港元
智通港股早知道 | 央行修订M1统计口径 香港11月整体楼宇买卖合约登记总值创4月来新高
智通财经 · 12-03
智通港股早知道 | 央行修订M1统计口径 香港11月整体楼宇买卖合约登记总值创4月来新高
康哲药业(00867.HK)获1类新药ABP-671独家商业化权利
阿斯达克财经 · 12-02
康哲药业(00867.HK)获1类新药ABP-671独家商业化权利
康哲药业签独家协议 推出痛风新药ABP-671
财中社 · 12-02
康哲药业签独家协议 推出痛风新药ABP-671
康哲药业(00867)获得治疗痛风及高尿酸血症的1类新药的独家商业化权利
智通财经 · 12-02
康哲药业(00867)获得治疗痛风及高尿酸血症的1类新药的独家商业化权利
南向资金11月29日净买入康哲药业64.20万股 连续3日增持
市场透视 · 12-02
南向资金11月29日净买入康哲药业64.20万股 连续3日增持
康哲药业自研减重创新药CMS-D005临床获批,卖药巨头的创新“突围战”
21世纪经济报道 · 11-28
康哲药业自研减重创新药CMS-D005临床获批,卖药巨头的创新“突围战”
金十数据整理:每日港股市场要闻速递(11月28日 周四)
美港电讯 · 11-28
金十数据整理:每日港股市场要闻速递(11月28日 周四)
音频 | 格隆汇11.28盘前要点—港A美股你需要关注的大事都在这
格隆汇 · 11-28
音频 | 格隆汇11.28盘前要点—港A美股你需要关注的大事都在这
康哲药业(00867.HK)创新药CMS-D005获准开展临床试验
阿斯达克财经 · 11-28
康哲药业(00867.HK)创新药CMS-D005获准开展临床试验
康哲药业创新药CMS-D005获临床试验批准
财中社 · 11-27
康哲药业创新药CMS-D005获临床试验批准
康哲药业(00867):创新药GLP-1R/GCGR双重激动剂CMS-D005获药物临床试验批准通知书
智通财经 · 11-27
康哲药业(00867):创新药GLP-1R/GCGR双重激动剂CMS-D005获药物临床试验批准通知书
康哲药业11月27日主力资金流出1万元 连续3日减仓
市场透视 · 11-27
康哲药业11月27日主力资金流出1万元 连续3日减仓
暂无数据
公司概况
公司名称:
康哲药业
所属市场:
SEHK
上市日期:
--
主营业务:
康哲药业控股有限公司是一家主要从事医药产品的制造、推广、营销及销售业务的香港投资控股公司。其直接网络主要产品包括黛力新、优思弗、新活素、莎尔福、亿活及施图伦滴眼液等。其代理商推广网络产品包括沙多力卡、伊诺舒及喜达康等。其产品用于治疗胃病、心脏病、外伤感染、肝病及眼疾等。
发行价格:
--
{"stockData":{"symbol":"00867","market":"HK","secType":"STK","nameCN":"康哲药业","latestPrice":7.41,"timestamp":1734682090012,"preClose":7.4,"halted":0,"volume":6380477,"delay":0,"floatShares":2439528512,"shares":2439528512,"eps":1.0503864,"marketStatus":"已收盘","marketStatusCode":5,"change":0.01,"latestTime":"12-20 16:08:10","open":7.25,"high":7.47,"low":7.25,"amount":47177000,"amplitude":0.02973,"askPrice":7.42,"askSize":148000,"bidPrice":7.41,"bidSize":7000,"shortable":3,"etf":0,"ttmEps":0.6099413595589492,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734917400000},"adr":0,"adjPreClose":7.4,"dividendRate":0.033152,"openAndCloseTimeList":[[1734658200000,1734667200000],[1734670800000,1734681600000]],"volumeRatio":1.716531,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00867/tweets","defaultTab":"tweets","newsList":[{"id":"2491465967","title":"康哲药业12月16日遭主力抛售922万元 环比增加479.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491465967","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491465967?lang=zh_cn&edition=full","pubTime":"2024-12-16 16:15","pubTimestamp":1734336926,"startTime":"0","endTime":"0","summary":"12月16日, 康哲药业股价跌2.79%,报收7.33元,成交金额3523万元,换手率0.20%,振幅3.45%,量比0.78。康哲药业今日主力资金净流出922万元,上一交易日主力净流出159万元,今日环比增加479.87%。该股近5个交易日下跌7.10%,主力资金累计净流出1538万元;近20日主力资金累计净流出2148万元,其中净流出天数为16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216161534ab7bc867&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216161534ab7bc867&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BYV24P56.USD","SG9999015945.SGD","IE00BMCWC346.EUR","BK1191","SG9999004220.SGD","SG9999015986.USD","BK1593","00867","LU2488822045.USD","SG9999015978.USD","SG9999015952.SGD"],"gpt_icon":0},{"id":"2491904686","title":"南向资金12月13日净卖出康哲药业203.50万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2491904686","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491904686?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:30","pubTimestamp":1734312611,"startTime":"0","endTime":"0","summary":"12月13日,南向资金减持康哲药业203.50万股连续3日减持。截止当日收盘,港股通共持有康哲药业22462.32万股,占流通股9.20%。康哲药业近5个交易日下跌4.07%,港股通累计减持378.60万股;近20个交易日下跌0.92%,港股通累计增持587.45万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093048a1f1a68d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093048a1f1a68d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BYV24P56.USD","SG9999015986.USD","SG9999015952.SGD","SG9999015945.SGD","BK1593","IE00BMCWC346.EUR","BK1191","SG9999004220.SGD","00867","LU2488822045.USD","SG9999015978.USD"],"gpt_icon":0},{"id":"2490880505","title":"康哲药业12月11日遭主力抛售554万元 环比增加282.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490880505","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490880505?lang=zh_cn&edition=full","pubTime":"2024-12-11 16:17","pubTimestamp":1733905034,"startTime":"0","endTime":"0","summary":"12月11日, 康哲药业股价跌1.94%,报收7.58元,成交金额7942万元,换手率0.43%,振幅4.92%,量比2.77。康哲药业今日主力资金净流出554万元,连续7日净流出,上一交易日主力净流出145万元,今日环比增加282.07%。该股近5个交易日下跌3.32%,主力资金累计净流出998万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流出1320万元,其中净流出天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211161747ab6efb75&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211161747ab6efb75&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00867","SG9999015978.USD","SG9999015952.SGD","LU2488822045.USD","SG9999015986.USD","BK1191","SG9999015945.SGD","BK1593","SG9999004220.SGD","IE00BMCWC346.EUR","IE00BYV24P56.USD"],"gpt_icon":0},{"id":"2490033262","title":"康哲药业(00867)创新药莱芙兰®开出全国首批处方 助力结直肠病变精准诊断","url":"https://stock-news.laohu8.com/highlight/detail?id=2490033262","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490033262?lang=zh_cn&edition=full","pubTime":"2024-12-10 08:47","pubTimestamp":1733791620,"startTime":"0","endTime":"0","summary":"12月6日,康哲药业发布消息,其创新药莱芙兰已开出全国首批处方,正式进入临床应用。这是中国首个口服亚甲蓝肠溶缓释片,用于在接受结肠镜检查筛查或监测的成人患者中增强结直肠病变的可视化。智通财经APP了解到,截至目前,康哲药业已有5款创新药在中国成功获批,并全面进入临床应用。面对日益增长的需求,莱芙兰的推出为中国结直肠病检查筛查和疾病管理提供了创新方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","BK1593","SG9999015945.SGD","SG9999015952.SGD","SG9999015986.USD","BK1574","IE00BMCWC346.EUR","BK1191","159992","06978","SG9999015978.USD","IE00BYV24P56.USD","BK1161","SG9999004220.SGD","00867"],"gpt_icon":0},{"id":"2490710421","title":"康哲药业12月09日遭主力抛售221万元 环比增加718.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490710421","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490710421?lang=zh_cn&edition=full","pubTime":"2024-12-09 16:15","pubTimestamp":1733732148,"startTime":"0","endTime":"0","summary":"12月09日, 康哲药业股价涨0.38%,报收7.89元,成交金额4749万元,换手率0.25%,振幅4.07%,量比2.31。康哲药业今日主力资金净流出221万元,连续5日净流出,上一交易日主力净流出27万元,今日环比增加718.52%。该股近5个交易日上涨0.90%,主力资金累计净流出509万元;近20日主力资金累计净流出703万元,其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209161607a1dfdd73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209161607a1dfdd73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00867","LU2488822045.USD","SG9999015945.SGD","BK1593","SG9999004220.SGD","SG9999015952.SGD","IE00BMCWC346.EUR","BK1191","SG9999015986.USD","SG9999015978.USD","IE00BYV24P56.USD"],"gpt_icon":0},{"id":"2489439428","title":"康哲药业12月05日主力资金流出52万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2489439428","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489439428?lang=zh_cn&edition=full","pubTime":"2024-12-05 16:16","pubTimestamp":1733386602,"startTime":"0","endTime":"0","summary":"12月05日, 康哲药业股价跌1.53%,报收7.72元,成交金额1779万元,换手率0.09%,振幅2.42%,量比0.96。康哲药业今日主力资金净流出52万元,连续3日净流出,上一交易日主力净流出126万元,今日环比减少58.73%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为40.00%,平均跌幅为2.33%。该股近5个交易日上涨0.65%,主力资金累计净流入13万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流出224万元,其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205161717ab5f3576&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205161717ab5f3576&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00867","SG9999015945.SGD","BK1593","SG9999015978.USD","BK1191","SG9999004220.SGD","SG9999015952.SGD","IE00BYV24P56.USD","SG9999015986.USD","IE00BMCWC346.EUR","LU2488822045.USD"],"gpt_icon":0},{"id":"2489103517","title":"高盛:维持康哲药业“买入”评级 目标价上调至12.82港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489103517","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489103517?lang=zh_cn&edition=full","pubTime":"2024-12-05 11:32","pubTimestamp":1733369520,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 高盛发布研究报告称,考虑到新产品,将康哲药业(00867)目标价从11.79港元上调8.7%至12.82港元,维持“买入”评级。该行认为,ABP-671是一种潜在有前景的痛风治疗选择。\n 报告中称,集团宣布与Atom\n Therapeutics签订独家协议,根据该协议,康哲药业将负责ABP-671在中国大陆、香港和澳门的商业化。回顾公司设定的2025-27年推出12种新产品的目标,持续引进后期资产的交付进度令人鼓舞。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:史丽君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2024-12-05/doc-incyknpq9952416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["00867"],"gpt_icon":0},{"id":"2489658108","title":"高盛:维持康哲药业(00867)“买入”评级 目标价上调至12.82港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489658108","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489658108?lang=zh_cn&edition=full","pubTime":"2024-12-05 11:08","pubTimestamp":1733368087,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,高盛发布研究报告称,考虑到新产品,将康哲药业(00867)目标价从11.79港元上调8.7%至12.82港元,维持“买入”评级。该行认为,ABP-671是一种潜在有前景的痛风治疗选择。报告中称,集团宣布与Atom Therapeutics签订独家协议,根据该协议,康哲药业将负责ABP-671在中国大陆、香港和澳门的商业化。回顾公司设定的2025-27年推出12种新产品的目标,持续引进后期资产的交付进度令人鼓舞。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00867"],"gpt_icon":0},{"id":"2488198719","title":"智通港股早知道 | 央行修订M1统计口径 香港11月整体楼宇买卖合约登记总值创4月来新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2488198719","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488198719?lang=zh_cn&edition=full","pubTime":"2024-12-03 07:18","pubTimestamp":1733181533,"startTime":"0","endTime":"0","summary":"香港11月份整体楼宇买卖合约登记总值环比上升53.8% 创今年4月来新高智通财经APP获悉,中原地产研究部高级联席董事杨明仪指出,11月份香港整体楼宇买卖合约登记7678宗,总值640.73亿港元,环比分别上升31.1%及53.8%,宗数及金额齐创今年4月后新高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1536","BK1133","HSTECH","SG9999015952.SGD","SG9999015978.USD","IE00BMCWC346.EUR","YANG","BK1593","SG9999015945.SGD","BK1191","LU2488822045.USD","SG9999015986.USD","00867","SG9999004220.SGD","BK1583","IE00BYV24P56.USD","01310","02096","HSCEI"],"gpt_icon":1},{"id":"2488244608","title":"康哲药业(00867.HK)获1类新药ABP-671独家商业化权利","url":"https://stock-news.laohu8.com/highlight/detail?id=2488244608","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488244608?lang=zh_cn&edition=full","pubTime":"2024-12-02 23:47","pubTimestamp":1733154420,"startTime":"0","endTime":"0","summary":"康哲药业(00867.HK) 公布,与新元素药业签订独家商业化协议,据此,集团获得治疗痛风及高尿酸血症的1类新药ABP-671在内地、香港及澳门的独家商业化权利。自产品首次在内地获批上市起拥有十年的授权期限。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-02 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230303150406244_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230303150406244_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1401203/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["00867","SG9999015978.USD","IE00BMCWC346.EUR","SG9999004220.SGD","SG9999015986.USD","SG9999015952.SGD","IE00BYV24P56.USD","SG9999015945.SGD","BK1191","BK1593","LU2488822045.USD"],"gpt_icon":0},{"id":"2488379673","title":"康哲药业签独家协议 推出痛风新药ABP-671","url":"https://stock-news.laohu8.com/highlight/detail?id=2488379673","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488379673?lang=zh_cn&edition=full","pubTime":"2024-12-02 19:46","pubTimestamp":1733139960,"startTime":"0","endTime":"0","summary":"财中社12月2日电康哲药业 发布公告,宣布其全资附属公司与杭州新元素药业有限公司签订了关于治疗痛风及高尿酸血症的1类新药ABP-671的独家商业化协议。ABP-671是一种用于治疗痛风及高尿酸血症的创新药物,目前正在进行2b/3期临床试验。公司预期该产品如获批上市,将对其业绩产生积极影响,满足临床对高效安全药物的需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202195816abefa8fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202195816abefa8fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999015945.SGD","SG9999015986.USD","SG9999015978.USD","00867","SG9999015952.SGD","IE00BMCWC346.EUR","IE00BYV24P56.USD","BK1593","SG9999004220.SGD","BK1191","LU2488822045.USD"],"gpt_icon":0},{"id":"2488620440","title":"康哲药业(00867)获得治疗痛风及高尿酸血症的1类新药的独家商业化权利","url":"https://stock-news.laohu8.com/highlight/detail?id=2488620440","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488620440?lang=zh_cn&edition=full","pubTime":"2024-12-02 19:29","pubTimestamp":1733138969,"startTime":"0","endTime":"0","summary":"据悉,ABP-671是用于治疗痛风及高尿酸血症的化药1类创新药,目前正分别在中国和境外开展关于痛风的2b/3期临床试验,产品通过抑制尿酸盐转运蛋白1,降低肾脏对尿酸的重吸收。产品有望为痛风及高尿酸血症患者带来疗效更优、安全性更高的治疗选择。治疗痛风及高尿酸血症的1类新药ABP-671的引进将填补集团痛风治疗产品的空白,将使集团创新药产品矩阵更加多元化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219224.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BYV24P56.USD","00867","SG9999015952.SGD","SG9999004220.SGD","LU2488822045.USD","BK1593","SG9999015945.SGD","BK1191","SG9999015986.USD","IE00BMCWC346.EUR","SG9999015978.USD"],"gpt_icon":0},{"id":"2488561921","title":"南向资金11月29日净买入康哲药业64.20万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2488561921","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488561921?lang=zh_cn&edition=full","pubTime":"2024-12-02 09:30","pubTimestamp":1733103009,"startTime":"0","endTime":"0","summary":"11月29日, 南向资金增持康哲药业64.20万股,连续3日增持。截止当日收盘,港股通共持有康哲药业22837.72万股,占流通股9.35%。康哲药业近5个交易日上涨6.53%,港股通累计增持287.30万股;近20个交易日下跌0.63%,港股通累计增持947.40万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202093037abee41d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202093037abee41d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","00867","LU2488822045.USD","IE00BMCWC346.EUR","SG9999004220.SGD","BK1191","SG9999015952.SGD","SG9999015978.USD","IE00BYV24P56.USD","SG9999015986.USD","SG9999015945.SGD"],"gpt_icon":0},{"id":"2486365619","title":"康哲药业自研减重创新药CMS-D005临床获批,卖药巨头的创新“突围战”","url":"https://stock-news.laohu8.com/highlight/detail?id=2486365619","media":"21世纪经济报道","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486365619?lang=zh_cn&edition=full","pubTime":"2024-11-28 15:20","pubTimestamp":1732778400,"startTime":"0","endTime":"0","summary":"11月27日,康哲药业公告,集团自主研发的创新药CMS-D005注射液获得国家药监局签发的药物临床试验批准通知书。同意集团在中国健康以及超重和肥胖成人受试者中开展评价CMS-D005安全性、耐受性及药代动力学和药效学特征的临床试验。未来,康哲药业的CMS-D005可开发用于治疗肥胖、超重,代谢相关脂肪性肝炎,2型糖尿病等多种代谢相关疾病。2018年,康哲药业宣布向创新药企转型。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128152211abe53337&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128152211abe53337&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1574","SG9999015945.SGD","SG9999015986.USD","06978","IE00BYV24P56.USD","SG9999004220.SGD","BK1191","LU2488822045.USD","SG9999015952.SGD","00867","SG9999015978.USD","IE00BMCWC346.EUR","BK1161"],"gpt_icon":0},{"id":"2486338469","title":"金十数据整理:每日港股市场要闻速递(11月28日 周四)","url":"https://stock-news.laohu8.com/highlight/detail?id=2486338469","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486338469?lang=zh_cn&edition=full","pubTime":"2024-11-28 09:10","pubTimestamp":1732756228,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["07226","BK1121","BK4588","161027","HSCEI","00867","IE00BYV24P56.USD","03692","BK1515","LU1894683348.USD","YANG","LU2488822045.USD","BK1208","01468","BK1521","BK1141","BK1227","BK1589","02105","08163","BK1574","GLP","LU2637428348.USD","02199","BK4585","BK4208","SG9999015952.SGD","03347","159992","BK1161","BK1138","01177","IE00BMCWC346.EUR","SG9999015986.USD","SG9999004220.SGD","06978","CMS","BK1593","BK1181","BK1185","02566","BK1576","HSTECH","BK4590","BK4144","LU2346227817.USD","BK1567","BK1583","01785"],"gpt_icon":0},{"id":"2486384699","title":"音频 | 格隆汇11.28盘前要点—港A美股你需要关注的大事都在这","url":"https://stock-news.laohu8.com/highlight/detail?id=2486384699","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486384699?lang=zh_cn&edition=full","pubTime":"2024-11-28 07:40","pubTimestamp":1732750833,"startTime":"0","endTime":"0","summary":"美股指数集体收跌,中概指数大涨2.81%;报复美国!加拿大正在研究;瑞银预计中国将推出15万亿元化债;低空经济、物流板块大消息!中办、国办发文;谷子经济爆火,近10家上市公司回应;内外资机构集体看多中国资产...","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/109.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/109.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1395163","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["00867","SG9999015945.SGD","BK1593","SG9999015978.USD","BK1191","SG9999004220.SGD","SG9999015952.SGD","IE00BYV24P56.USD","SG9999015986.USD","IE00BMCWC346.EUR","LU2488822045.USD"],"gpt_icon":0},{"id":"2486870204","title":"康哲药业(00867.HK)创新药CMS-D005获准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2486870204","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486870204?lang=zh_cn&edition=full","pubTime":"2024-11-28 01:52","pubTimestamp":1732729920,"startTime":"0","endTime":"0","summary":"康哲药业(00867.HK) 公布,集团自主研发的创新药CMS-D005注射液获中国国家药品监督管理局签发药物临床试验批准,同意集团在内地健康以及超重和肥胖成人受试者中开展评价CMS-D005安全性、耐受性及药代动力学和药效学特征的临床试验。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-27 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1400021/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["IE00BMCWC346.EUR","159992","BK1593","BK1161","SG9999015978.USD","06978","00867","BK1191","SG9999015945.SGD","03347","SG9999015986.USD","LU2488822045.USD","BK1583","BK1574","SG9999004220.SGD","IE00BYV24P56.USD","SG9999015952.SGD","BK1141","BK1576"],"gpt_icon":0},{"id":"2486828012","title":"康哲药业创新药CMS-D005获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486828012","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486828012?lang=zh_cn&edition=full","pubTime":"2024-11-27 20:05","pubTimestamp":1732709100,"startTime":"0","endTime":"0","summary":"财中社11月27日电康哲药业 发布自愿性及业务进展公告,宣布其自主研发的创新药CMS-D005于2024年11月27日获得中国国家药品监督管理局签发的药物临床试验批准通知书。该临床试验将在中国对健康以及超重和肥胖成人受试者进行,旨在评估CMS-D005的安全性、耐受性及药代动力学和药效学特征。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127200858a259ae12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127200858a259ae12&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","IE00BYV24P56.USD","SG9999015986.USD","SG9999015952.SGD","BK1141","BK1574","SG9999015945.SGD","BK1593","IE00BMCWC346.EUR","BK1583","BK1191","BK1576","06978","SG9999004220.SGD","00867","BK1161","LU2488822045.USD","SG9999015978.USD"],"gpt_icon":0},{"id":"2486478868","title":"康哲药业(00867):创新药GLP-1R/GCGR双重激动剂CMS-D005获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2486478868","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486478868?lang=zh_cn&edition=full","pubTime":"2024-11-27 19:18","pubTimestamp":1732706293,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康哲药业 发布公告,该集团欣然宣布,集团自主研发的创新药CMS-D005注射液于2024年11月27日获得中国国家药品监督管理局签发的药物临床试验批准通知书。NMPA同意集团在中国健康以及超重和肥胖成人受试者中开展评价CMS-D005安全性、耐受性及药代动力学和药效学特征的临床试验。临床前研究显示CMS-D005对GLP-1R和GCGR有很强的激动活性,具有良好减重效果和安全性,显示用于超重或肥胖症治疗的良好前景。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1216815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4590","GLP","BK1576","159992","03347","BK4585","BK1191","SG9999004220.SGD","BK4588","BK1141","SG9999015978.USD","SG9999015952.SGD","BK4144","LU2637428348.USD","LU2346227817.USD","00867","CMS","BK1583","IE00BYV24P56.USD","LU1894683348.USD","LU1894683264.USD","BK4208","IE00BMCWC346.EUR","06978","LU2488822045.USD","BK1161","SG9999015945.SGD","BK1574","SG9999015986.USD","BK1593"],"gpt_icon":0},{"id":"2486817782","title":"康哲药业11月27日主力资金流出1万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2486817782","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486817782?lang=zh_cn&edition=full","pubTime":"2024-11-27 16:15","pubTimestamp":1732695358,"startTime":"0","endTime":"0","summary":"11月27日, 康哲药业股价涨3.20%,报收7.75元,成交金额2487万元,换手率0.13%,振幅3.73%,量比0.64。康哲药业今日主力资金净流出1万元,连续3日净流出,上一交易日主力净流出9万元,今日环比减少88.89%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为33.33%,平均跌幅为1.79%。该股近5个交易日上涨1.17%,主力资金累计净流入189万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流出384万元,其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127161622a2593926&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127161622a2593926&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1191","SG9999015952.SGD","00867","IE00BYV24P56.USD","SG9999015945.SGD","IE00BMCWC346.EUR","SG9999015986.USD","SG9999015978.USD","SG9999004220.SGD","LU2488822045.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cms.net.cn","stockEarnings":[{"period":"1week","weight":-0.039},{"period":"1month","weight":-0.039},{"period":"3month","weight":-0.0537},{"period":"6month","weight":0.0911},{"period":"1year","weight":-0.4302},{"period":"ytd","weight":-0.4466}],"compareEarnings":[{"period":"1week","weight":-0.0316},{"period":"1month","weight":0.0045},{"period":"3month","weight":0.0818},{"period":"6month","weight":0.0956},{"period":"1year","weight":0.1889},{"period":"ytd","weight":0.1587}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康哲药业控股有限公司是一家主要从事医药产品的制造、推广、营销及销售业务的香港投资控股公司。其直接网络主要产品包括黛力新、优思弗、新活素、莎尔福、亿活及施图伦滴眼液等。其代理商推广网络产品包括沙多力卡、伊诺舒及喜达康等。其产品用于治疗胃病、心脏病、外伤感染、肝病及眼疾等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.011301},{"month":2,"riseRate":0.538462,"avgChangeRate":0.023837},{"month":3,"riseRate":0.5,"avgChangeRate":0.004124},{"month":4,"riseRate":0.5,"avgChangeRate":0.02223},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.008532},{"month":6,"riseRate":0.642857,"avgChangeRate":-0.002183},{"month":7,"riseRate":0.5,"avgChangeRate":-0.017299},{"month":8,"riseRate":0.428571,"avgChangeRate":0.023866},{"month":9,"riseRate":0.428571,"avgChangeRate":0.001076},{"month":10,"riseRate":0.533333,"avgChangeRate":0.011646},{"month":11,"riseRate":0.6,"avgChangeRate":0.058536},{"month":12,"riseRate":0.6,"avgChangeRate":0.037339}],"exchange":"SEHK","name":"康哲药业","nameEN":"CMS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康哲药业(00867)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康哲药业(00867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康哲药业,00867,康哲药业股票,康哲药业股票老虎,康哲药业股票老虎国际,康哲药业行情,康哲药业股票行情,康哲药业股价,康哲药业股市,康哲药业股票价格,康哲药业股票交易,康哲药业股票购买,康哲药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康哲药业(00867)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康哲药业(00867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}